NEW YORK – T2 Biosystems today announced it entered into exclusive agreements with five new distribution partners in the first half of 2019, enabling it to introduce its rapid diagnostic tests in Estonia, Greece, Ireland, Saudi Arabia, and South Africa. These countries have about 1,170 hospitals that could benefit from its products, the firm said.
Financial and other terms of the agreement were not disclosed. T2 Bio also did not disclose the names of the distribution partners.
Running on T2MR, the firm's miniaturized magnetic resonance instrument, its diagnostic panels rapidly detect sepsis-causing bacterial and fungal pathogens directly from whole blood in less than five hours and without the need to wait for a blood culture.
John McDonough, president and CEO of Lexington, Massachusetts-based T2, said in a statement that the company anticipates "adding partners in new geographies in the second half of the year and beyond."
The firm now has products in 33 countries including the US.